Plus Therapeutics Inc. held a Special Meeting of Stockholders on May 2, 2025. Stockholders approved a Certificate of Amendment to increase the authorized shares of common stock from 100,000,000 to 2,000,000,000. Discretionary authority was granted to the Board to conduct a reverse stock split at a ratio between one-for-twenty-five and one-for-two-hundred-fifty, to be executed within twelve months. Additionally, stockholders authorized the issuance of shares in compliance with Nasdaq Listing Rule 5635(d).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.